GlassScriptPhysician profile
Sarah Gutierrez
NPI 1861842346
$2,615.59
in general payments reported to CMS, 2019-2025
23 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $1,569 · 2023: $179 · 2024: $63.46 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $712.75 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $340.51 | 2022 | |
| Neurelis, INC. | $240.45 | 2021-2022 | |
| Abbvie INC. | $239.50 | 2024-2025 | |
| Aquestive Therapeutics, INC. | $188.64 | 2021-2022 | |
| Corium, LLC | $125.81 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $85.05 | 2021 | |
| Neurocrine Biosciences, INC. | $83.30 | 2023 | Ingrezza |
| Aprecia Pharmaceuticals, LLC | $81.73 | 2022 | |
| Sunovion Pharmaceuticals INC. | $79.04 | 2022 | |
| Supernus Pharmaceuticals, INC. | $61.92 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.29 | 2021 | |
| Janssen Scientific Affairs, LLC | $50.86 | 2023 | Invega Sustenna, Invega Trinza, Spravato |
| Livanova USA, INC. | $48.52 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $42.67 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.89 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $22.00 | 2023 | Austedo Xr |
| Medtronic, INC. | $20.77 | 2024 | Nexpowder |
| Eisai INC. | $16.28 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.02 | 2021 | |
| Alkermes, INC. | $14.83 | 2024 | Lybalvi |
| Adlon Therapeutics L.P. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.